

YMTHE, Volume 27

## **Supplemental Information**

**AAV6 Is Superior to**

**Clade F AAVs in**

**Stimulating**

**Homologous**

**Recombination-Based**

**Genome Editing in**

**Human HSPCs**

**Amanda M. Dudek and Matthew H. Porteus**

**Methods:****Plasmids:**

pKanAAV2/6.2 and pKanAAV2/9 was a gift from L.H. Vandenberghe. Site-directed mutagenesis kit (Agilent #200524) was used to generate pKanAAV2/6, and pKanAAV2/9 variants. pAdΔF6 was a gift from James M. Wilson (Addgene plasmid #112867). HBB donor construct has been described previously.<sup>26</sup>

**Molecular modeling:**

The AAV9 60-mer was assembled in Mac pymol from the AAV9 crystal structure<sup>28</sup> PDB: 3UX1 and is represented as a surface rendering with heat map demonstrating the B-factor and individual VP3 monomer chains within the capsid trimer highlighted white, grey, or black. The location of the mutations generated by site-directed mutagenesis of the AAV9 capsid are highlighted magenta.

**CD34+ HSPC isolation and cell culture:**

CD34+ HSPCs were isolated from fresh cord blood using human CD34 UltraPure MicroBeads (Miltenyi 130-100-453) provided by the Binns Family program for Cord Blood Research. Cells were cultured in StemSpan SFEMII (Stemcell technologies) supplemented with stem cell factor (SCF) (100 ng/mL), thrombopoietin (TPO) (100 ng/mL), FLT3-ligand (100 ng/mL), IL-6 (100 ng/mL), 20mg/mL penicillin, and 20mg/mL streptomycin at 37°C, 5% CO<sub>2</sub> and 5% O<sub>2</sub>.

**AAV production and titration:**

12 million 293T cells per dish in 5 15-cm dishes were plated 1 day prior to three-plasmid transfection with 26 μg pAdΔF6, 13 μg pKanAAV2/(cap), and 13 μg HBB donor transgene per plate using PEI. 48-72 hours post-transfection cell-associated vector was harvested from cell pellets using the AAVpro Purification Kit (Takara #6666). Genomic DNA from purified vector was extracted using QuickExtract DNA Extraction Solution (Lucigen #QE09050) followed by titration by ddPCR using AAV2 ITR-specific primer/probe.<sup>41</sup>

**AAV transduction, targeting, and analysis:**

CD34+ cell editing and AAV transduction was done as previously described.<sup>15, 24, 42</sup> Briefly, RNP complex was generated using sgRNA target sequence for *HBB*: 5' - CTTGCCCCACAGGGCAGTAA-3' and WT Cas9 by incubation at room temperature for 15-20 minutes and electroporated into CD34+ cells using Lonza 4D Nucleofector (program DZ100). AAV was added at 5,000 VG/cell immediately after electroporation and then cells were diluted and cultured at 100,000 cells/mL. Editing and transduction was done after 2-3 days in culture with addition of fresh cytokine-containing media every 48 hours. GFP positive cells were analyzed on a FACSAria II SORP (BD Biosciences) 12-14 days after targeting.

**References**

41. Aurnhammer, C., Haase, M., Muether, N., Hausl, M., Rauschhuber, C., Huber, I., Nitschko, H., Busch, U., Sing, A., Ehrhardt, A., and Baiker, A. (2012). Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. *Hum. Gene Ther. Methods* 23, 18–28.
42. Bak, R.O., Dever, D.P., Reinisch, A., Cruz Hernandez, D., Majeti, R., and Porteus, M.H. (2017). Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6. *eLife* 6, 6.